Latest News

Wen Shen, MD, outlines when to treat perimenopausal symptoms and which history-taking red flags should prompt earlier bone and cardiovascular screening or referral.

Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.

Missed the rollout of ACOG's 2026 Maternal Immunization Schedule? This FAQ breaks down everything clinicians need to know about the new guidance.

Jean Cunningham, PharmD, BCPS, explains how ob-gyns can link anxiety, sleep disruption, and cognitive changes to perimenopause—and catch it earlier.

The well-woman visit drives preventive care, but its structure leaves little room for the complexity of women's lives, according to Barbara Levy, MD.

A review finds post-miscarriage ultrasound heterogeneity is common and that symptoms, not endometrial thickness, should guide management after EPL.

Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.

Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.

Wen Shen, MD, describes perimenopause as an opportunity for clinicians to revisit pregnancy-related risk factors and address cardiovascular health proactively.

A new study finds that low birth volume and unprofitability were strongly associated with both obstetric unit and full hospital closures between 2010 and 2023.

A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.

A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.

Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.

Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.

A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.

The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.

AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.

CDC data show gestational hypertension rose 73% from 2016 to 2024, affecting 1 in 10 US mothers giving birth.

Missed the updated IDSA histoplasmosis guideline? This easy-to-read FAQ covers what clinicians caring for pregnant patients need to know.

The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.

In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about PCOS, the push to rename it PMOS, and why diagnostic delays so often begin in adolescence.

Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.

Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.

Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.

Hosted by Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, the monthly series brings clinicians, researchers, innovators, advocates, and other voices across women’s health into conversations that rarely happen in the same room.

A new book from Sameena Rahman, MD, reclaims "brown girls' disease" as a lens for examining how dismissal—of conditions, anatomy, and patients—undermines sexual medicine care for all women.

Menopause proteomics were consistently associated with inflammatory brain aging and Alzheimer’s dementia risk across nearly 15,000 women in a new study published in Nature Medicine.

The FDA approved an IDE allowing Mercy BioAnalytics to evaluate its Evident blood-based ovarian cancer screening test in the prospective pivotal SOARA study of average-risk women.

Sameena Rahman, MD, discusses how digital symptom trackers can shorten PMOS diagnostic delays and support earlier cardiometabolic care.

A new, expert-led video series explores the PCOS-to-PMOS rename and what it means for diagnosis, care, and outcomes.

Seventy-one percent of women miss their first perimenopausal symptom because anxiety, brain fog, and mood changes precede hot flashes—and most attribute them to stress, per the Bonafide 2026 State of Menopause Survey.